Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
April 27, 2015 10:41 AM EDT
UBS analyst Matthew Roden reiterated a Neutral rating but raised his price target on Biogen (NASDAQ: BIIB) to $422.00 (from $350.00) following Q1 results. While they remain cautious on expected revisions to Tecfidera estimates they are positive on AD.
Roden's key takeaways from the call:
[1] Gross to net adjustments were higher this quarter for Tecfidera in part... More
April 24, 2015 3:32 PM EDT
BMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over 6% after the company reported Q1 results that missed consensus. In the view of analyst Jim Birchenough, weakness is overdone and represents a buying opportunity.
"We are reaffirming... More
April 24, 2015 7:01 AM EDT
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.82, versus the analyst estimate of $3.88. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.66 billion.
First Quarter 2015 Performance Highlights
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year.TECFIDERA revenues...
More
